ERBB2 and breast cancer: A retrospective cohort of 168 patients with HER2-positive BC revealed a median PFS of 8.8 months (95%CI 6.6–11.0) in patient with BM (n = 39) who were heavily pre-treated with HER2-targeted agents [86].